- Welcome and Overview
- Multidisciplinary Approaches to Biomarker Testing and Targeted Therapy in Advanced
- Colorectal Cancer
- Gastric, Esophageal, and Gastroesophageal Junction Cancers
- Pancreatic and Biliary Tract Cancers
- Live Audience Question and Answer Session
Scott Kopetz, MD, PhD, FACP
Department of Gastrointestinal Medical Oncology
University of Texas MD Anderson Cancer Center
Dipen M. Maru, MD
Department of Pathology
The University of Texas MD Anderson Cancer Center
The goal of this educational curriculum is to improve the knowledge, competence, and performance of learners to optimally diagnose gastrointestinal cancers that have a biomarker predictive for treatment benefit and plan individualized treatment based on current and emerging therapeutic strategies for patients with gastrointestinal cancers.
This program is intended for oncologists and pathologists who care for patients with gastrointestinal cancers.
- Apply the available data and expert recommendations to determine which biomarkers should be assessed in patients with GI malignancies
- Implement best practices for molecular testing in GI cancers, including the use of tissue-based biomarker testing for evaluation of BRAF V600E, HER2/HER3, BRCA1/2, FGFR2, IDH1, and tumor agnostic markers
- Plan therapeutic strategies for patients with GI malignancies based on predictive biomarker assessment to improve duration and quality of life
- Evaluate the clinical validity, utility, and differences among single biomarker companion diagnostics and available comprehensive genomic testing platforms using next-generation sequencing
- Appraise ongoing clinical trials for novel biomarker-driven treatment strategies in GI malignancies for patient counsel and potential enrollment
Joint Accreditation Statement
In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
American Board of Pathology Continuing Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Lifelong Learning point in the American Board of Pathology’s Maintenance of Certification (MOC) Program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit learner completion information to ACCME for the purpose of granting ABPath Continuing Certification (formerly Maintenance of Certification or MOC) credit.
American Board of Internal Medicine Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.